Community Financial Services Group LLC Buys New Shares in Johnson & Johnson (NYSE:JNJ)

Community Financial Services Group LLC acquired a new position in Johnson & Johnson (NYSE:JNJFree Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 26,918 shares of the company’s stock, valued at approximately $4,193,000. Johnson & Johnson makes up about 1.1% of Community Financial Services Group LLC’s investment portfolio, making the stock its 27th largest holding.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Hibernia Wealth Partners LLC purchased a new position in Johnson & Johnson in the third quarter valued at about $27,000. FNY Investment Advisers LLC bought a new position in Johnson & Johnson in the 3rd quarter worth approximately $37,000. Tower View Wealth Management LLC boosted its holdings in Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after buying an additional 165 shares during the period. Creative Capital Management Investments LLC boosted its holdings in Johnson & Johnson by 43.0% in the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares during the period. Finally, VitalStone Financial LLC bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $48,000. 68.40% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on JNJ shares. Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, January 24th. Finally, Raymond James raised their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $176.14.

Check Out Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $156.74 on Friday. The stock has a market cap of $377.32 billion, a PE ratio of 11.35, a PEG ratio of 2.65 and a beta of 0.53. The company’s fifty day moving average is $158.20 and its 200 day moving average is $158.93. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The firm’s revenue was down 9.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.35 EPS. Research analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s payout ratio is presently 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.